Evidence map›Paper›PMID 42697939›Full record

ArticleScientific reports2026

Enhancing short-term predictions of mortality risk for liver transplant candidates through random survival forests.

Roni Ramon-Gonen, Dana Bielopolski, Shiri Kushnir, Ofir Ben-Assuli, Eviatar Nesher, Amir Shlomai

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roni Ramon-GonenInformation Systems Program, The Graduate School of Business Administration, Bar-Ilan University, Ramat-Gan, Israel.
Dana BielopolskiThe Department of Organ Transplantation, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
Shiri KushnirResearch Authority, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
Ofir Ben-AssuliInformation System Department, The Faculty of Business Administration, Ono Academic College, Kiryat Ono, Israel.
Eviatar NesherThe Department of Organ Transplantation, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
Amir ShlomaiDepartment of Medicine D, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel. shlomaiamir@gmail.com.ORCID 0000-0001-7437-9381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MELD-based scores do not fully account for systemic and metabolic risk in liver transplant candidates, with notable gaps for those with metabolic dysfunction-associated steatotic liver disease (MASLD). In this retrospective, outcome-anchored, single-center proof-of-concept study, we analyzed adult patients listed for liver transplantation at our institute from 2004 to 2025. We analyzed clinical and laboratory data collected 3-12 months prior to death, transplantation, or censoring, focusing on advanced disease stages. Exclusion criteria included hepatocellular carcinoma and incomplete MELD 3.0 data. We developed a competing-risk random survival forest (RSF) model using nine metabolic and systemic variables, and compared its performance to MELD-Na and MELD 3.0 via time-dependent discrimination and calibration metrics. Among 434 candidates (median age 56.8 years, 60.4% male), 43.3% died on the waitlist, 45.6% underwent transplantation, and 11.1% were alive at study end. The RSF model showed numerically higher discrimination for 180-day waitlist mortality (AUC = 0.81) versus MELD 3.0 and MELD-Na (AUC = 0.75 each), but this exploratory improvement did not demonstrate statistically significant superiority in pairwise AUC comparison. Albumin, diabetes mellitus, and hemoglobin were the strongest predictors. Exploratory reclassification analyses demonstrated a positive Net Reclassification Index (NRI = 0.30), driven primarily by improved identification of patients who died on the waiting list, with minimal misclassification among survivors. Exploratory subgroup analyses showed numerically higher discrimination among candidates with MASLD. These findings support further evaluation of the RSF model as a research framework for outcome-anchored 180-day waitlist mortality assessment. Prospective, multicenter, and external validation will be required before any consideration of clinical use.

Indexed as

Liver TransplantationWaiting ListsAgedFemaleHumansMaleMiddle AgedRandom ForestRetrospective StudiesRisk Assessment180-day waitlist mortalityLiver transplantationMachine-learning modelMELD 3.0Risk assessmentRSF model

Identifiers

PMID42697939
PMCPMC13545214

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.